The novel tellurium immunomodulator AS101 inhibits interleukin-10 production and p38 MAPK expression in atopic dermatitis.
The immunomodulator, AS101, inhibits production of IL-10, IL-4 and expression of p38 MAPK, while increasing production of IFNgamma and IL-2. Together with its excellent clinical safety profile in humans, suggests a potential therapeutic use for AD.